Literature DB >> 18336298

Isoform-selective histone deacetylase inhibitors.

Yukihiro Itoh1, Takayoshi Suzuki, Naoki Miyata.   

Abstract

Histone deacetylases (HDACs) catalyze the deacetylation of the acetylated lysine residues of histones and non-histone proteins, and are involved in various fundamental life phenomena, such as gene expression and cell cycle progression. Thus far, eighteen HDAC family members have been identified and they can be divided into two categories, i.e., zinc-dependent enzymes (HDAC1-11) and NAD(+)-dependent enzymes (SIRT1-7). Some of the HDAC isoforms have important roles in cell functions, and are associated with various disease states, including cancer. Therefore, isoform-selective HDAC inhibitors are of great interest, not only as tools for probing the biological functions of the isoforms, but also as candidate therapeutic agents with few side effects. In this review, we cover isoform-selective HDAC inhibitors, including their biochemical and pharmacological functions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18336298     DOI: 10.2174/138161208783885335

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  28 in total

1.  Regulation of CRADD-caspase 2 cascade by histone deacetylase 1 in gastric cancer.

Authors:  Qi Shen; Wanfen Tang; Jie Sun; Lifeng Feng; Hongchuan Jin; Xian Wang
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

Review 2.  Macrocyclic histone deacetylase inhibitors.

Authors:  Sandra C Mwakwari; Vishal Patil; William Guerrant; Adegboyega K Oyelere
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

3.  Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.

Authors:  Erin M Bowers; Gai Yan; Chandrani Mukherjee; Andrew Orry; Ling Wang; Marc A Holbert; Nicholas T Crump; Catherine A Hazzalin; Glen Liszczak; Hua Yuan; Cecilia Larocca; S Adrian Saldanha; Ruben Abagyan; Yan Sun; David J Meyers; Ronen Marmorstein; Louis C Mahadevan; Rhoda M Alani; Philip A Cole
Journal:  Chem Biol       Date:  2010-05-28

4.  Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.

Authors:  Sandra C Mwakwari; William Guerrant; Vishal Patil; Shabana I Khan; Babu L Tekwani; Zachary A Gurard-Levin; Milan Mrksich; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2010-08-26       Impact factor: 7.446

5.  Thiol-Based Potent and Selective HDAC6 Inhibitors Promote Tubulin Acetylation and T-Regulatory Cell Suppressive Function.

Authors:  Mariana C F Segretti; Gian Paolo Vallerini; Camille Brochier; Brett Langley; Liqing Wang; Wayne W Hancock; Alan P Kozikowski
Journal:  ACS Med Chem Lett       Date:  2015-10-05       Impact factor: 4.345

Review 6.  Chemical probes for histone-modifying enzymes.

Authors:  Philip A Cole
Journal:  Nat Chem Biol       Date:  2008-10       Impact factor: 15.040

7.  Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases.

Authors:  C James Chou; David Herman; Joel M Gottesfeld
Journal:  J Biol Chem       Date:  2008-10-24       Impact factor: 5.157

Review 8.  Multiple roles of HDAC inhibition in neurodegenerative conditions.

Authors:  De-Maw Chuang; Yan Leng; Zoya Marinova; Hyeon-Ju Kim; Chi-Tso Chiu
Journal:  Trends Neurosci       Date:  2009-09-21       Impact factor: 13.837

9.  Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.

Authors:  Annunziata Gloghini; Daniela Buglio; Noor M Khaskhely; Georgios Georgakis; Robert Z Orlowski; Sattva S Neelapu; Antonino Carbone; Anas Younes
Journal:  Br J Haematol       Date:  2009-09-22       Impact factor: 6.998

10.  Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes.

Authors:  Angela Nebbioso; Fabio Manzo; Marco Miceli; Mariarosaria Conte; Lucrezia Manente; Alfonso Baldi; Antonio De Luca; Dante Rotili; Sergio Valente; Antonello Mai; Alessandro Usiello; Hinrich Gronemeyer; Lucia Altucci
Journal:  EMBO Rep       Date:  2009-06-05       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.